Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth
In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more. To get it in your inbox, subscribe here. Eli Lilly CEO David Ricks Getty Images Lilly’s GLP-1 business is booming. The company …